Daré Bioscience receives $2.5 million for contraceptive tech

The company has been recognized for its contributions to women's health innovation and advocacy, earning accolades such as a top ranking in the San Diego Business Journal's Best Places to Work Awards for 2023. Despite showing strong revenue growth of 88% over the last twelve months, InvestingPro analysis suggests the stock is currently overvalued. Investors seeking deeper insights can access comprehensive financial analysis and additional ProTips through the Pro Research Report, available exclusively to InvestingPro subscribers. Despite showing strong revenue growth of 88% over the last twelve months, InvestingPro analysis suggests the stock is currently overvalued. Investors seeking deeper insights can access comprehensive financial analysis and additional ProTips through the Pro Research Report, available exclusively to InvestingPro subscribers.

The DARE-LARC1 platform is being designed as a long-acting, reversible contraceptive (LARC) with unique features including precision dosing, extended duration, and wireless control. Utilizing levonorgestrel, an active ingredient in several FDA-approved contraceptives, DARE-LARC1 aims to offer women extended effective contraception without the need for daily intervention.

The company has been recognized for its contributions to women's health innovation and advocacy, earning accolades such as a top ranking in the San Diego Business Journal's Best Places to Work Awards for 2023. Despite showing strong revenue growth of 88% over the last twelve months, InvestingPro analysis suggests the stock is currently overvalued. Investors seeking deeper insights can access comprehensive financial analysis and additional ProTips through the Pro Research Report, available exclusively to InvestingPro subscribers.

In pursuit of expanding the technology's reach beyond reproductive health, Daré is engaging in strategic discussions with potential industry partners. The implant's features, including a custom battery designed to last up to 20 years and smartphone integration, underscore its innovative approach to drug delivery.

Daré Bioscience's commitment to advancing women's health is evident in its diverse portfolio, which includes the FDA-approved XACIATO™ for bacterial vaginosis and candidates like Ovaprene®, a hormone-free contraceptive, and Sildenafil Cream for female sexual arousal disorder.

The company has been recognized for its contributions to women's health innovation and advocacy, earning accolades such as a top ranking in the San Diego Business Journal's Best Places to Work Awards for 2023.

This recent financial milestone is part of Daré's ongoing efforts to meet specific development and reporting milestones required to receive additional grant payments. The progress of DARE-LARC1 and the strategic collaborations pursued by Daré reflect its dedication to addressing unmet needs in healthcare. The information in this article is based on a press release statement from Daré Bioscience.

In other recent news, Daré Bioscience, Inc. reported its third-quarter financial results and the progress of its women's health product pipeline. The company secured over $20 million in non-dilutive funding, which will support the development of key products. Despite a comprehensive loss of $4.7 million for the quarter, Daré highlighted a decrease in R&D and administrative expenses, maintaining a cash position of $11.2 million. The company is also collaborating with Bayer (OTC:BAYRY) and has received significant funding from ARPA-H and the Gates Foundation. Key products like Ovaprene, a hormone-free contraceptive, and Sildenafil Cream for female sexual arousal disorder are advancing through clinical trials. Daré is expected to begin the Ovaprene study in 2024, with the addition of new sites expected to improve enrollment efficiency. These are the recent developments in the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.